Skip to content
PubMed This is a summary of 14 peer-reviewed journal articles Updated
Medical Genetics

Multidisciplinary Care and Emergency Management

At a Glance

Managing PMM2-CDG requires a multidisciplinary medical team led by a metabolic geneticist. Because patients face acute risks like abnormal clotting and stroke-like episodes triggered by fevers or head injuries, families must carry a formal emergency protocol letter at all times.

Managing PMM2-CDG is not a journey you take alone. Because the condition can affect multiple organs at once, it requires a “team-based” approach. While there is currently no curative therapy, proactive and supportive care—guided by international medical standards—can significantly improve your child’s quality of life and safety [1][2].

Building Your Multidisciplinary Care Team

International guidelines, specifically the Schiff et al. 2020 guidelines, emphasize that patients with PMM2-CDG need regular monitoring from a variety of specialists [1]. Your core team should ideally include:

  • Metabolic Geneticist: The “quarterback” of the team who understands the underlying biochemistry [1].
  • Pediatric Neurologist: To monitor development, balance (ataxia), and manage any potential seizures [3][4].
  • Hepatologist (Liver Specialist): To track liver enzymes and monitor for signs of liver stress or hepatomegaly (enlarged liver) [5][6].
  • Cardiologist: To perform regular checks (EKGs and echocardiograms) for issues like pericardial effusion (fluid around the heart) [7][8].
  • Endocrinologist: To monitor for adrenal insufficiency (where the body doesn’t make enough stress hormones) and issues with blood sugar [9][10].
  • Therapy Team: Physical, occupational, and speech therapists are vital for supporting motor skills, feeding, and communication [11].

Emergency Protocols: What You Need to Know

Certain aspects of PMM2-CDG require immediate action during illness or injury. Parents should be prepared for two specific “acute” risks:

1. Abnormal Hemostasis (Clotting & Bleeding)

Many patients with PMM2-CDG have chronic imbalances in their blood chemistry. Specifically, they may have low levels of Antithrombin III, which helps prevent blood clots, alongside imbalances in factors that help the blood clot when needed [12].

  • Risk: This can lead to an increased risk of either bleeding (in about 16% of patients) or dangerous blood clots (in about 10% of patients) [12]. Because this biological paradox can be frightening, it is important to know the physical signs to watch for at home.
  • Signs to Watch For: For bleeding, look for unexplained bruising or prolonged nosebleeds. For clotting, watch for sudden, localized swelling, redness, or warmth in an arm or leg. If you see these signs, seek emergency medical care [13].
  • Surgical Note: During surgeries or major injuries, specific replacements for these factors may be required [13].

2. Stroke-Like Episodes (SLEs)

These are sudden, temporary events that look like a stroke—such as weakness on one side of the body or confusion [14]. They are often triggered by a high fever or a minor head injury [13].

  • Emergency Step: If your child shows signs of an SLE, they must be evaluated by a neurologist immediately. Managing fevers “aggressively” is a key preventative measure. This means not waiting for the fever to get high—administering fever reducers at a lower temperature threshold (e.g., immediately at 100.4°F), keeping the child well-hydrated, and closely monitoring them during any illness [13].

The Importance of an Emergency Letter

Because PMM2-CDG is rare, an ER doctor or paramedic may not know how to treat it. It is essential to carry an Emergency Letter (sometimes called a “Metabolic Protocol”) signed by your specialist [13]. You should also provide copies of this letter to the school nurse, daycare providers, and local EMS dispatchers [13]. This letter should include:

  • A brief explanation of PMM2-CDG.
  • The “baseline” lab values.
  • Specific instructions for managing fevers, hydration, and coagulation risks.
  • Emergency contact numbers for the metabolic geneticist [9].

Vetting Your Specialists

When choosing a local doctor, don’t be afraid to ask direct questions to ensure they have the expertise—or the willingness to learn—needed for a rare disease:

  • “How many other patients with CDGs or similar metabolic disorders have you treated?”
  • “Are you willing to collaborate directly with a major CDG research center for my child’s care?”
  • “What is your plan for staying updated on the latest international management guidelines for PMM2-CDG?”
  • “How do you handle after-hours emergencies for patients with complex genetic conditions?”

Common questions in this guide

What specialists should be on my child's PMM2-CDG care team?
A comprehensive care team is typically led by a metabolic geneticist and should include a pediatric neurologist, hepatologist, cardiologist, and endocrinologist. Physical, occupational, and speech therapists are also essential for supporting daily development and communication.
Why do PMM2-CDG patients have risks for both bleeding and clotting?
Patients with PMM2-CDG have chronic imbalances in their blood chemistry, such as low Antithrombin III levels. This creates a biological paradox where they are at an increased risk for both abnormal bleeding and dangerous blood clots.
What triggers stroke-like episodes in PMM2-CDG?
Stroke-like episodes are sudden events causing weakness or confusion that mimic a stroke. In patients with PMM2-CDG, these episodes are frequently triggered by a high fever or a minor head injury, which is why aggressive fever management is critical.
Why do we need an emergency letter for PMM2-CDG?
Because PMM2-CDG is extremely rare, emergency room doctors may not be familiar with it. An emergency letter outlines your child's baseline lab values, specific instructions for managing fevers, and necessary coagulation protocols to ensure safe, immediate treatment.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Are you familiar with the Schiff et al. 2020 international guidelines for PMM2-CDG management?
  2. 2.Which metabolic geneticist or CDG expert will be the primary coordinator for our child's multidisciplinary team?
  3. 3.Can we work together to draft a formal Emergency Letter that includes specific protocols for Antithrombin III replacement and stroke-like episode management?
  4. 4.What is our child's current baseline for liver enzymes, coagulation factors, and adrenal function?
  5. 5.How will you coordinate information between the various specialists (neurology, cardiology, hepatology) to ensure everyone is on the same page?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (14)
  1. 1

    International clinical guidelines for the management of phosphomannomutase 2-congenital disorders of glycosylation: Diagnosis, treatment and follow up.

    Altassan R, Péanne R, Jaeken J, et al.

    Journal of inherited metabolic disease 2019; (42(1)):5-28 doi:10.1002/jimd.12024.

    PMID: 30740725
  2. 2

    [Advances in the diagnosis and treatment of phosphomannomutase 2 deficiency].

    Zhou SY

    Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics 2023; (25(2)):223-228 doi:10.7499/j.issn.1008-8830.2209049.

    PMID: 36854702
  3. 3

    Neurodevelopmental profiles of 14 individuals with phosphomannomutase deficiency (PMM2-CDG).

    Weixel T, Adedipe D, Muldoon G, et al.

    Journal of inherited metabolic disease 2025; (48(1)):e12782 doi:10.1002/jimd.12782.

    PMID: 39105373
  4. 4

    Neurological manifestations in PMM2-congenital disorders of glycosylation (PMM2-CDG): Insights into clinico-radiological characteristics, recommendations for follow-up, and future directions.

    Muthusamy K, Perez-Ortiz JM, Ligezka AN, et al.

    Genetics in medicine : official journal of the American College of Medical Genetics 2024; (26(2)):101027 doi:10.1016/j.gim.2023.101027.

    PMID: 37955240
  5. 5

    Liver manifestations in a cohort of 39 patients with congenital disorders of glycosylation: pin-pointing the characteristics of liver injury and proposing recommendations for follow-up.

    Starosta RT, Boyer S, Tahata S, et al.

    Orphanet journal of rare diseases 2021; (16(1)):20 doi:10.1186/s13023-020-01630-2.

    PMID: 33413482
  6. 6

    Clinical, laboratory and molecular findings and long-term follow-up data in 96 French patients with PMM2-CDG (phosphomannomutase 2-congenital disorder of glycosylation) and review of the literature.

    Schiff M, Roda C, Monin ML, et al.

    Journal of medical genetics 2017; (54(12)):843-851 doi:10.1136/jmedgenet-2017-104903.

    PMID: 28954837
  7. 7

    Cardiomyopathy, an uncommon phenotype of congenital disorders of glycosylation: Recommendations for baseline screening and follow-up evaluation.

    Zemet R, Hope KD, Edmondson AC, et al.

    Molecular genetics and metabolism 2024; (142(4)):108513 doi:10.1016/j.ymgme.2024.108513.

    PMID: 38917675
  8. 8

    Novel Splicing Variant in the PMM2 Gene in a Patient With PMM2-CDG Syndrome Presenting With Pericardial Effusion: A Case Report.

    Slaba K, Noskova H, Vesela P, et al.

    Frontiers in genetics 2020; (11()):561054 doi:10.3389/fgene.2020.561054.

    PMID: 33133147
  9. 9

    Should patients with Phosphomannomutase 2-CDG (PMM2-CDG) be screened for adrenal insufficiency?

    Čechová A, Honzík T, Edmondson AC, et al.

    Molecular genetics and metabolism 2021; (133(4)):397-399 doi:10.1016/j.ymgme.2021.06.003.

    PMID: 34140212
  10. 10

    Suspected Central Adrenal Insufficiency in a Patient with Phosphomannomutase 2-Congenital Disorder of Glycosylation.

    Ødum SF, Grønborg SW, Main KM, Klose M

    JCEM case reports 2025; (3(11)):luaf237 doi:10.1210/jcemcr/luaf237.

    PMID: 41080975
  11. 11

    Motor improvement in children with PMM2-CDG syndrome following a six-month rehabilitation treatment utilising whole-body vibration; a retrospective study.

    Bossier C, Stark C, Martakis K, et al.

    Journal of musculoskeletal & neuronal interactions 2024; (24(1)):12-21.

    PMID: 38427364
  12. 12

    Coagulation abnormalities in a prospective cohort of 50 patients with PMM2-congenital disorder of glycosylation.

    De Graef D, Ligezka AN, Rezents J, et al.

    Molecular genetics and metabolism 2023; (139(2)):107606 doi:10.1016/j.ymgme.2023.107606.

    PMID: 37224763
  13. 13

    Association between acute complications in PMM2-CDG patients and haemostasis anomalies: Data from a multicentric study and suggestions for acute management.

    Wicker C, Roux CJ, Goujon L, et al.

    Molecular genetics and metabolism 2023; (140(3)):107674 doi:10.1016/j.ymgme.2023.107674.

    PMID: 37542768
  14. 14

    Stroke-Like Episodes in PMM2-CDG: When the Lack of Other Evidence Is the Only Evidence.

    Serrano M

    Frontiers in pediatrics 2021; (9()):717864 doi:10.3389/fped.2021.717864.

    PMID: 34708008

This page provides educational information about multidisciplinary care and emergency protocols for PMM2-CDG. Always consult your metabolic geneticist or emergency physician for medical advice and to create an individualized emergency letter.

Get notified when new evidence is published on PMM2-CDG.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.